Johnson & Johnson (UKEX:JNJ)
â‚´ 5947 0 (0%) Market Cap: 14.82 Til Enterprise Value: 15.47 Til PE Ratio: 24.01 PB Ratio: 4.98 GF Score: 84/100

Johnson & Johnson Pharmaceutical Business Review Transcript

Nov 18, 2021 / 01:30PM GMT
Unidentified Participant

Welcome to the Johnson & Johnson 2021 Business Review Meeting, Highlighting Pharmaceuticals.

Please note that today's presentation includes forward-looking statements. We encourage you to review the cautionary statement included in today's presentation, which identify certain factors that may cause the company's actual results to differ materially from those projected. Our SEC filings, along with reconciliations of any non-GAAP financial measures utilized to the most comparable GAAP measures, are also available at investor.jnj.com.

Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. These slides acknowledge those relationships.

Ladies and gentlemen, please welcome Vice President of Investor Relations, Jessica Moore.

Jessica Moore
Johnson & Johnson - VP of IR

Good morning, everyone, or good afternoon, evening to some of you joining on our virtual platform. It is a great honor to be standing before

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot